3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
12
HER2-positive Breast Cancer
6
Carcinoma, Non-Small-Cell Lung
2
Triple Negative Breast Neoplasms
1
Salivary Gland Neoplasms
1
Rare Tumor
1
Lung Neoplasms
1
Locally Advanced Breast Cancer
1
HER2-positive Metastatic Breast Cancer
1
HER2-positive Early Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
HER2-expressing Advanced Solid Tumors
1
HER2 Positive Breast Cancer
1
HER2 Insertion Mutation Positive Advanced NSCLC
1
Esophageal Squamous Cell Carcinoma
1
Breast Neoplasm Female
1
Breast Cancer Metastatic
1
Breast Cancer Invasive
1
Breast Cancer Female
1
Advanced Breast Cancer
1
Interventions
pembrolizumab
57
Carboplatin
34
Paclitaxel
24
Cyclophosphamide
23
Capecitabine
18
sacituzumab govitecan
16
Specimen Handling
15
130-nm albumin-bound paclitaxel
15
toripalimab
11
Drug Therapy
11
Biopsy
11
Magnetic Resonance Spectroscopy
10
Bevacizumab
10
Taxes
9
Epirubicin
9
durvalumab
8
Albumin-Bound Paclitaxel
8
olaparib
7
camrelizumab
7
Gemcitabine
7
Doxorubicin
7
Docetaxel
7
fludarabine
6
famitinib
5
Nivolumab
5
Injections
5
atezolizumab
4
abemaciclib
4
Trastuzumab
4
Standard of Care
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Triple Negative Breast Neoplasms
×
pyrotinib
×
Clear all
NCT05582499
2026-05-28
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled